Frequency of positivity of the tuberculin intradermorreaction test in a cohort of patients with rheumatoid arthritis
Abstract
Introduction: Rheumatoid arthritis is an autoimmune, chronic, and deforming condition associated with disability. Patients are immunosuppressed and at high risk of developing tuberculosis. The tuberculin skin test is used to screen candidates for biological therapy.
Objective: To evaluate the frequency of positivity of the tuberculin skin test in a cohort of Colombian patients with rheumatoid arthritis.
Materials and methods: We conducted a descriptive cross-sectional study including patients with rheumatoid arthritis receiving the tuberculin skin test prior to the start or at the time of the change of biological therapy. The patients’ condition was moderate or severe and they were candidates for initiation or change of biological therapy. We defined the value of ≥6 mm as the cut-off point for a positive tuberculin skin test and performed a descriptive analysis for each of the variables considered.
Results: In total, 261 patients with rheumatoid arthritis were included, 92 % of whom were women; the average age was 55 years (SD=13.92) and the time from diagnosis, 12.3 years (SD=8.54). The frequency of positive tuberculin skin tests was 15.71% (n=41). Of the 41 positive patients, nine had previously had the test (1 to 6 years before), all of them with negative results; 18 of these were receiving glucocorticoids (43.9%) and all of them (100%) were being treated with methotrexate.
Conclusions: The frequency of positivity of the tuberculin skin test in these Colombian patients diagnosed with rheumatoid arthritis was around 16%. We reco0mmend optimizing strategies aimed at an optimal detection of this condition and the timely initiation of treatment to reduce the risk of tuberculosis reactivation.
Downloads
References
Smolen JS, Aletaha D, Barton A, Burmester G, Emery P, Firestein G, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. https://doi.org/10.1038/nrdp.2018.1
Bautista-Molano W, Fernández-Ávila D, Jiménez R, Cardozo R, Marín A, Soler MP, Gómez O, Ruiz O. Perfil epidemiológico de pacientes colombianos con artritis reumatoide evaluados n una clínica especializada de atención integral. Reumatol Clin. 2016;12:313-8. https://doi.org/10.1016/j.reuma.2015.11.009
Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52:1986-92. https://doi.org/10.1002/art.21137
Smolen JS, Landewé RBM, Bijlsma JW, Burmester G, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic
and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685-99 https://doi.org/10.1136/annrheumdis-2019-216655
Kauffman SH. New issues in tuberculosis. Ann Rheum Dis. 2004;63 (Suppl.2):50-6. https://doi.org/10.1136/ard.2004.028258
Zar HJ, Udwadia ZF. Advances in tuberculosis 2011-2012. Thorax. 2013;68:283-7. https://doi.org/10.1136/thoraxjnl-2012-203127
Corbett EL, Watt CJ, Walker N, Maher D, Willliams B, Raviglione M, et al. The growing burden of tuberculosis global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009-21. https://10.1001/archinte.163.9.1009
Raviglione M. Global tuberculosis report 2015, World Health Organization. Fecha de consulta: 9 de noviembre de 2017. Disponible en: http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf
Chaparro PE, García I, Guerrero MI, León CI. Situación de la tuberculosis en Colombia, 2002. Biomédica. 2004;24(Suppl.1):102-14. https://doi.org/10.7705/biomedica.v24iSupp1.1309
López-Pérez M. Informe de evento tuberculosis en Colombia 2018. Fecha de consulta: 1 de diciembre de 2020. Disponible en: https://www.ins.gov.co/buscador-eventos/Informesdeevento/TUBERCULOSIS_2018.pdf
Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: Differential modes of action of infliximab and etanercept? Clin Infect Dis. 2005;41(Suppl.3):S199-S203. https://doi.org/10.1086/429998
Gómez-Reino JJ, Carmona L, Valverde VR, Martín-Mola E, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122-7. https://doi.org/10.1002/art.11137
O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Ann Rev Immmunol. 2013;31:475-527. https://doi.org/10.1146/annurev-immunol-032712-095939
Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P, et al. Interferongamma release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014;189:77-87. https://doi.org/10.1164/rccm.201302-0365OC
Pai M, Denkinger CM, Kik SV, Rangaka M, Zwerling A, Oxlade O, et al. Gamma Interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27:3-20. https://doi.org/10.1128/CMR.00034-13
Dannenberg AM. Delayed-type hypersensitivity and cell mediated immunity in the pathogenesis of tuberculosis. Immunol Today. 1991;12:229-33. https://doi.org/10.1016/0167-5699(91)90035-R
Pérez C, Borda A. Interpretación de la PPD, fundamentos fisiopatológicos y enfoque práctico. Rev Colomb Neumol. 2007;19:11-7.
American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221-47. https://doi.org/10.1164/ajrccm.161.supplement_3.ats600
Forero E, Chalem M, Vásquez G, Jauregui E, Medina L, Pinto L, et al. Risk management for prescribing biological therapies. Rev Colomb Reumatol. 2016;23:50-67. https://doi.org/10.1016/j.rcreu.2016.02.004
Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522-8. https://doi.org/10.1136/ard.2009.118935
Chung TT, Ko HJ, Lau CS, Chung HY. A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis. Rheumatol Int. 2020;40:1-8. https://doi.org/10.1007/s00296-020-04583-8
Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med. 2006;174:736-42. https://doi.org/10.1164/rccm.200509-1516PP
López-Pérez M. Informe final. Tuberculosis, Colombia, 2014. Fecha de consulta: 29 de abril de 2016. Disponible en: http://www.ins.gov.co/lineas-de-accion/Subdireccion-Vigilancia/Informe%20de%20Evento%20Epidemiolgico/Tuberculosis%202014.pdf
Zafari P, Golpour M, Hafezi N, Bashash D, Esmaeli S, Golpour M, et al. Tuberculosis comorbidity with rheumatoid arthritis: Gene signatures, associated biomarkers, and screening. IUBMB Life. 2020;73:26-39. https://doi.org/10.1002/iub.2413
Tamborenea MN, Tate G, Mysler E, Debonis J, Schiledman A. Prevalence of positive PPD in a cohort of rheumatoid arthritis patients. Rheumatol Int. 2010;30:613-6. https://doi.org/10.1007/s00296-009-1027-z
Bautista-Molano W, Landewé R, Burgos-Vargas R, Maldonado-Cocco J, Molto A, van den Bosch F, et al. Prevalence of comorbidities and risk factors for comorbidities in patients with spondyloarthritis in Latin America: A comparative study with the general population and data from the ASAS-COMOSPA Study. J Rheumatol. 2018;45:206-12. https://doi.org/10.3899/jrheum.170520
Pahal P, Sharma S. PPD Skin Test. Treasure Island (FL): Stat Pearls Publishing; 2020. Fecha de consulta: 25 de marzo de 2020. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK556037/
Small PM, Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med. 2001;345:189-200. https://doi.org/10.1056/NEJM200107193450307
Some similar items:
- John-Leonardo Torres-Castiblanco, Jorge Alberto Carrillo, Daniel Hincapié-Urrego, Adriana Rojas-Villarraga, Tuberculosis in the era of anti-TNF-alpha therapy: Why does the risk still exist? , Biomedica: Vol. 38 No. 1 (2018)
- Nelson José Alvis-Zakzuk, María de los Ángeles Carrasquilla, Verónica Jhajaira Gómez, Jaime Robledo, Nelson Rafael Alvis-Guzmán, José Mauricio Hernández, Diagnostic accuracy of three technologies for the diagnosis of multi-drug resistant tuberculosis , Biomedica: Vol. 37 No. 3 (2017)
- Juan Gabriel Bueno-Sánchez, Jairo René Martínez-Morales, Elena E. Stashenko, Wellman Ribón, Anti-tubercular activity of eleven aromatic and medicinal plants occurring in Colombia , Biomedica: Vol. 29 No. 1 (2009)
- María Consuelo Garzón, Dailyn Yorledy Angée, Claudia Llerena, Dora Leticia Orjuela, Jorge Ernesto Victoria, Surveillance of Mycobacterium tuberculosis resistance to antituberculosis drugs , Biomedica: Vol. 28 No. 3 (2008)
- Leandro Galvis, Ángel Y. Sánchez, Leonardo F. Jurado, Martha I. Murcia, Tuberculosis associated with tumor necrosis factor-α antagonists, case description and analysis of reported cases in Colombia , Biomedica: Vol. 38 No. 1 (2018)
- Diego Chaves, Andrea Sandoval, Luis Rodríguez, Juan C. García, Silvia Restrepo, María Mercedes Zambrano, Comparative analysis of six Mycobacterium tuberculosis complex genomes , Biomedica: Vol. 30 No. 1 (2010)
- María Imaz, Sonia Allassia, Mónica Aranibar, Alba Gunia, Susana Poggi, Ana Togneri, Lidia Wolff, Group of Implementation of Fluorescence, Performance of LED fluorescence microscopy for the detection of acid-fast bacilli from respiratory samples in peripheral laboratories in Argentina , Biomedica: Vol. 37 No. 2 (2017)
- Luis Miguel Sosa, Luz Libia Cala, Julio César Mantilla, Congenital tuberculosis associated with maternal disseminated miliary tuberculosis , Biomedica: Vol. 27 No. 4 (2007)
- Gloria Mercedes Puerto , Claudia Marcela Castro , Vivian Vanesa Rubio , Santiago Fadul, Fernando Montes , Drug-resistant tuberculosis in Colombia, 2013-2018: Case-control study , Biomedica: Vol. 43 No. 4 (2023)
- Adriana Rojas-Villarraga, Carlos Andrés Agudelo, Ricardo Pineda-Tamayo, Alvaro Porras, Gustavo Matute, Juan Manuel Anaya, Tuberculosis in patientes treated with tumor necrosis factor alpha antagonists living in an endemic area. Is the risk worthwhile? , Biomedica: Vol. 27 No. 2 (2007)
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
